Claims for Patent: 7,074,400

Summary for Patent: 7,074,400

Title:	Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene
Abstract:	The invention provides regulatory constructs comprising intron 3 of the prostate specific membrane antigen gene (PSMA). An isolated nucleic acid molecule encoding the partial sequence of intron 3 of PSMA, a vector and a recombinant expression cassette are disclosed. The invention also provides a method of directing expression of a coding sequence in a prostate cell, a bladder cell, a breast cell and a vascular endothelial cell using the said constructs. This invention further provides a method of treatment of cancer using the said constructs.
Inventor(s):	Molloy; Peter Laurence (Chatswood, AU), Watt; Fujiko (Rozelle, AU)
Assignee:	The Commonwealth of Australia (Campbell, AU)
Application Number:	09/914,651
Patent Claims:	1. A recombinant polynucleotide comprising at least one enhancer element obtained from intron 3 of the PSM gene operably linked to a sequence encoding a heterologous polypeptide. 2. A recombinant polynucleotide according to claim 1 in which the recombinant polynucleotide further comprises a promoter. 3. A recombinant polynucleotide according to claim 1 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 14930 as shown in FIG. 11 or a sequence which hybridises thereto under high stringency. 4. A recombinant polynucleotide according to claim 1 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 15091 as shown in FIG. 11 or a sequence which hybridises thereto under high stringency. 5. A recombinant polynucleotide according to claim 1 in which the polynucleotide comprises two or more enhancer elements obtained from intron 3 of the PSM gene. 6. A recombinant polynucleotide according to claim 2 in which the promoter is located upstream from and is operably linked to the sequence encoding the heterologous polypeptide. 7. A recombinant polynucleotide according to claim 2 in which the promoter is selected from the group consisting of a herpes virus thymidine kinase (TK) promoter, a Rous sarcoma virus (RSV) promoter, a promoter active in the prostate, or a promoter active in the vascular endothelium. 8. A recombinant polynucleotide according to claim 6 in which the enhancer element comprises: (a) a sequence comprising nucleotides 14,045 to 15,804, nucleotides 14,760 to 15,804, nucleotides 14,760 to 16,575 or nucleotides 14,045 to 16,575 of the PSM gene; or (b) a nucleic acid sequence which hybridises under high stringency 0.1.times.SSC and 0.1% (w/v) SDS at 50.degree. C. wash conditions to a sequence defined in paragraph (a). 9. A recombinant polynucleotide according to claim 7 in which the promoter active in the prostate is selected from the group consisting of a probasin promoter, a PSM promoter and a PSA promoter. 10. A recombinant polynucleotide according to claim 9 in which the promoter active in the prostate is a PSM promoter. 11. A recombinant expression cassette comprising at least one enhancer element obtained from intron 3 of the PSM gene operably linked to a promoter, and an insertion site into which a coding sequence is optionally inserted, the insertion site being operably linked to and downstream of the promoter. 12. A recombinant expression cassette according to claim 11 in which the enhancer element is upstream of the promoter. 13. A recombinant expression cassette according to claim 11 in which the enhancer element comprises (a) a sequence comprising nucleotides 14,045 to 15,804, nucleotides 14,760 to 15,804, nucleotides 14,760 to 16,575 or nucleotides 14,045 to 16,575 of the PSM gene; or (b) a nucleic acid sequence which hybridises under high stringency 0.1.times.SSC and 0.1% (w/v) SDS at 50.degree. C. wash conditions to a sequence defined in paragraph (a). 14. A recombinant expression cassette according to claim 11 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 14930 as shown in FIG. 11 or a sequence which hybridises thereto under high stringency 0.1.times.SSC and 0.1% (w/v) SDS at 50.degree. C. wash conditions. 15. A recombinant expression cassette according to claim 11 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 15091 as shown in FIG. 11 or a sequence which hybridises thereto under high stringency 0.1.times.SSC and 0.1% (w/v) SDS at 50.degree. C. wash conditions. 16. A recombinant expression cassette according to claim 11 in which the expression cassette comprises two or more enhancer elements obtained from intron 3 of the PSM gene. 17. A recombinant expression cassette according claim 11 in which the expression cassette comprises a dimer or higher multimer comprising two or more enhancer elements obtained from intron 3 of the PSM gene. 18. A recombinant expression cassette according to claim 11 in which the promoter is selected from the group consisting of a herpes virus thymidine kinase (TK) promoter, a Rous sarcoma virus (RSV) promoter, a promoter active in the prostate, or a promoter active in the vascular endothelium. 19. A recombinant expression cassette according to claim 11 in which the expression cassette further comprises a polyadenylation signal located downstream from and operably linked to the coding sequence or downstream from the insertion site. 20. A recombinant expression cassette according to claim 18 in which the promoter active in the prostate is selected from the group consisting of a probasin promoter, a PSM promoter and a PSA promoter. 21. A recombinant expression cassette according to claim 20 in which the promoter active in the prostate is a PSM promoter. 22. A recombinant expression cassette according to claim 19 in which the polyadenylation signal is the SV40 polyadenylation signal or the bovine growth hormone polyadenylation signal. 23. A vector comprising a gene encoding a selectable marker and an isolated nucleic acid molecule, the nucleic acid molecule having enhancer activity and comprising: (a) a sequence comprising nucleotides 14760 to 14930 as shown in FIG. 11, or (b) a nucleic acid sequence which hybridises under high stringency 0.1.times.SSC and 0.1% (w/v) SDS at 50.degree. C. wash conditions to the sequence defined in Paragraph (a). 24. A vector according to claim 23 in which the vector is a human adenovirus Type 5 or ovine adenovirus. 25. A method for directing expression of a coding sequence in a prostate cell, the method comprising introducing into the cell a recombinant expression cassette comprising at least one enhancer element obtained from intron 3 of the PSM gene, a promoter, and a coding sequence, wherein the enhancer element and promoter direct expression of the coding sequence. 26. A method according to claim 25 in which the enhancer element comprises (a) a sequence comprising nucleotides 14,045 to 15,804, nucleotides 14,760 to 15,804, nucleotides 14,760 to 16,575 or nucleotides 14,045 to 16,575 of the PSM gene; or (b) a nucleic acid sequence which hybridises under high stringency 0.1.times.SSC and 0.1% (w/v) SDS at 50.degree. C. wash conditions to a sequence defined in paragraph (a). 27. A method according to claim 25 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 14930 as shown in FIG. 11 or a sequence which hybridises thereto under high stringency 0.1.times.SSC and 0.1% (w/v) SDS at 50.degree. C. wash conditions. 28. A method according to claim 25 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 15091 as shown in FIG. 11 or a sequence which hybridises thereto under high stringency 0.1.times.SSC and 0.1% (w/v) SDS at 50.degree. C. wash conditions. 29. A method according to claim 25 in which the promoter is selected from the group consisting of a herpes virus thymidine kinase (TK) promoter, a Rous sarcoma virus (RSV) promoter, or a promoter active in the prostate. 30. The method according to claim 25 in which the coding sequence encodes a toxin, a protein involved in viral replication, or an enzyme which converts a prodrug to a toxic drug. 31. A method according to claim 29 in which the promoter active in the prostate is selected from the group consisting of a probasin promoter, a PSM promoter and a PSA promoter. 32. A method according to claim 31 in which the promoter active in the prostate is a PSM promoter. 33. A method for the treatment of prostate cancer which method comprises administering to a subject a recombinant expression cassette comprising at least one enhancer element obtained from intron 3 of the PSM gene, a promoter, and a coding sequence, wherein the enhance element and promoter direct expression of the coding sequence. 34. A method according to claim 33 in which the enhancer element comprises (a) a sequence comprising nucleotides 14,045 to 15,804, nucleotides 14,760 to 15,804, nucleotides 14,760 to 16,575 or nucleotides 14,045 to 16,575 of the PSM gene; or (b) a nucleic acid sequence which hybridises under high stringency 0.1.times.SSC and 0.1% (w/v) SDS at 50.degree. C. wash conditions to a sequence defined in paragraph (a). 35. A method according to claim 33 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 14930 as shown in FIG. 11 or a sequence which hybridises thereto under high stringency 0.1.times.SSC and 0.1% (w/v) SDS at 50.degree. C. wash conditions. 36. A method according to claim 33 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 15091 as shown in FIG. 11 or a sequence which hybridises thereto under high stringency 0.1.times.SSC and 0.1% (w/v) SDS at 50.degree. C. wash conditions. 37. A method according to claim 33 in which the promoter is selected from the group consisting of a herpes virus thymidine kinase (TK) promoter, a Rous sarcoma virus (RSV) promoter, a promoter active in the prostate, or a promoter active in the vascular endothelium. 38. A method according to claim 33 in which the coding sequence encodes the enzyme purine nucleoside phosphorylase (PNP). 39. The method according to claim 33 in which the coding sequence encodes a toxin, a protein involved in viral replication, or an enzyme which converts a prodrug to a toxic drug. 40. A method according to claim 37 in which the promoter active in the prostate is selected from the group consisting of a probasin promoter, a PSM promoter and a PSA promoter. 41. A method according to claim 40 in which the promoter active in the prostate is a PSM promoter. 42. A method for directing in vitro expression of a coding sequence in a cell, the method comprising introducing into the cell a recombinant expression cassette comprising at least one enhancer element obtained from intron 3 of the PSM gene, a promoter, and a coding sequence, wherein the enhancer element and promoter direct expression of the coding sequence. 43. The method according to claim 30 in which the coding sequence encodes an enzyme which converts a prodrug to a toxic drug. 44. The method according to claim 43 in which the enzyme is purine nucleoside phosphorylase (PNP). 45. The method according to claim 39 in which the coding sequence encodes an enzyme which converts a prodrug to a toxic drug. 46. The method according to claim 45 in which the enzyme is purine nucleoside phosphorylase (PNP). 47. A vector comprising a gene encoding a selectable marker and an isolated nucleic acid molecule, the nucleic acid molecule having enhancer activity and comprising: (a) a sequence comprising nucleotides 14760 to 15091 as shown in FIG. 11, or (b) a nucleic acid sequence which hybridises under high stringency 0.1.times.SSC and 0.1% (w/v) SDS at 50.degree. C. wash conditions to the sequence defined in paragraph (a). 48. A vector according to claim 47 in which the vector is a human adenovirus Type 5 or ovine adenovirus.

Details for Patent 7,074,400

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-03-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-03-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-03-01